Expert Interview
Examining Alnylam's pipeline in treating cardiac amyloidosis
Ticker(s): ALNYInstitution: Brigham and Women's | Harvard
- Associate Physician in Cardiovascular Medicine at BWH and an Instructor in Medicine at Harvard Medical School.
- Manages 200 patients with cardiac amyloidosis.
- Research interests have focused on the use of imaging in cardiac amyloidosis, particularly for early detection of disease and to track response to therapy; site-PI in two large multi-center phase 3 trials of novel gene-silencers in transthyretin cardiac amyloidosis (ATTR).
Roughly how many patients with cardiac amyloidosis do you currently manage?
Added By: c_adminWhat has your experience to date been with Onpattro?
Added By: c_adminIf Onpattro is approved for cardiomyopathy in addition to its current indication for polyneuropathy of hATTR amyloidosis, does the ability to treat both indications make it more likely that you would use it in your practice vs Tafamidis?
Similar question for Vutrisiran, which, if approved would be injected rather than infused like Onpattro, is approved for cardiomyopathy in addition to its pending indication for polyneuropathy of hATTR amyloidosis, does the ability to
treat both indications make it more likely that you would use it in your
practice vs Tafamidis?
Broadly speaking, how would you view the use of Onpattro vs Tafamidis?
Some other KOLs we have spoken with have indicated the possibility of performing combination therapy with patisiran and tafamidis. What is your view on this kind of regimen?
Added By: user14a46d1eAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
